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Summary. Recent studies have shown that angiotensin con- 
verting enzyme (ACE) inhibitor treatment in young sponta- 
neously hypertensive rats (SHR) reduces blood pressure into 
adulthood. This study explored changes in vascular reactivity 
in adult normotensive (WKY) rats and stroke-prone SHR 
(SHRSP) receiving the following treatments at 6-10 weeks 
of age: (a) ACE inhibitor (ramipril); (b) hydralazine/hydro- 
chlorothiazide (hydral/HCTZ); or (c) no treatment. The hy- 
pothesis tested was that vascular changes and blood pressure 
would be reduced in adult SHRSP treated with ramipril dur- 
ing development. At 17 weeks of age, rats were anesthetized 
and vascular tissue was excised. Isolated experiments in the 
aorta included characterization of initial phasic and tonic 
contractions to 0.1 ~LM angiotensin II (AII). A phenylephrine 
(PE) concentration-response curve was performed on carotid 
arteries, and threshold values were determined. All WKY 
groups showed lower systolic blood pressure (131 _ 4 mmHg) 
and reduced phasic AII induced contraction (7.4 ± 4.7%) 
compared with SHRSP (217 ± 4 mmHg; 37.2 -+ 4%). Antihy- 
pertensive treatment reduced blood pressure (ramipril: 168 _+ 
2; hydral/HCTZ: 198 ± 6 mmHg) but not phasic AII responses 
in adult SHRSP; adult WKY rats were unaffected by treat- 
ment. Threshold values for PE in carotid arteries were lower 
in SHRSP than in WKY, indicating increased sensitivity. 
However, SHRSP treated with ramipril did not demonstrate 
increased sensitivity to PE. These data support the hypothe- 
sis that blood pressure and sensitivity to PE but not contrac- 
tile responsiveness to AII in adult SHRSP are determined by 
an AII-sensitive mechanism during development. 
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Curren t  evidence suggests that hereditary factors 
play an important role in the enhanced vascular reac- 
tivity in genetic hypertension [1,2]. Several recent 
studies have shown increased vascular responsiveness 
to agonists [3,4] in genetically hypertensive rats  
(SHR). Further,  several of these enhanced responses 
were associated with elevated blood pressure [5]. 
Recent investigations have focused on development 
aspects of hypertension. Specifically, the role that  the 
renin-angiotensin system plays in the expression of 
genetic hypertension has come under scrutiny. Sev- 
eral studies have shown that  SHR treated with an 
angiotensin converting enzyme (ACE) inhibitor dur- 
ing a so-called critical period of development (2-10 
weeks of life) do not elevate arterial blood pressure 
to the same magnitude as that  observed in untreated 
SHR or in SHR treated with the ACE inhibitor dur- 
ing a noncritical period [6-10]. I t  has been postulated 
that these effects may be due to prevention of gene 
switching. This switching appears to represent  an 
adaptive response to recruit genes that  are normally 
active only during fetal development and that  code for 
proteins that are responsible for the maintenance of 
elevated blood pressure in adulthood. These studies, 
however, failed to characterize vascular responses to 
agonists that  have been observed to be different in 
SHR in comparison with normotensive (WKY) rats. 
The goals of the present  study were as follows: (1) 
to examine vascular responses in stroke-prone SHR 
(SHRSP) that  differ from WKY and how these traits 
are affected by blocking the generation of angiotensin 
I I  (AII) during development; and (2) to control for the 
direct effect of lower blood pressure during the critical 
period by using a non-angiotensin-dependent antihy- 
pertensive treatment.  The hypotheses tested were 
that abnormal vascular responses and blood pressure 
may be reduced in adult SHRSP treated with ramipril 
at an early age and that  reversal  of the vascular ab- 
normalities in hypertension may be independent of the 
blood pressure-lowering effect of ACE inhibitors. 
M a t e r i a l s  a n d  M e t h o d s  
Animal  t reatment  
Male SHRSP and WKY rats were obtained from a 
colony maintained in the Department  of Anatomy and 
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Cell Biology at the University of Michigan (Ann 
Arbor, MI). All rats were housed in a light-cycled, 
temperature-controlled room with ad libitum access 
to food and water. At all times excluding the 6-10 
week age period, rats received tap water and stan- 
dard laboratory chow (Purina Mills Co., Richmond, 
IN). Body weight was recorded and systolic blood 
pressure was measured weekly. Systolic blood pres- 
sure was measured by an indirect tail cuff (pneumatic 
transducer) method in conscious, restrained rats. 
Three experimental treatment regimens were in- 
cluded in this protocol: untreated (WKY, n = 8; 
SHRSP, n = 8), ACE inhibitor treated (WKY, n = 
8; SHRSP, n = 8), and diuretic/vasodilator treated 
(WKY, n = 6; SHRSP, n = 6). One untreated WKY 
and one SHRSP diuretic/vasodilator-treated rat did 
not survive the study and were excluded from the 
analysis. Rats in the diuretic/vasodilator group re- 
ceived hydralazine (200 mg/1) and hydrochlorothiazide 
(200 mg/1) in their drinking water during the treat- 
ment period. Based on an intake of 20 ml of water per 
day, rats received 4 mg/day of each drug. All other 
rats received tap water. Rats in the ACE inhibitor- 
treated group were given ramipril in their food 
(0.0025% ramipril by weight) from 6 to 10 weeks of 
age. Measured dosages of ramipril were WKY, 2.94 
-+ 0.16 mg/kg/day and SHRSP 3.23 _ 0.18 mg/kg/ 
day (p > 0.05). All other rats received control food. 
Experimental protocol 
At 17 weeks of age, rats were anesthetized with so- 
dium pentobarbital (50 mg/kg) and decapitated. Tho- 
racic aortae and carotid arteries were harvested and 
placed in cold physiological salt solution (PSS composi- 
tion in mmol/1 was as follows: NaC1 130, KC1 4.7, 
KH2PO 4 1.18, MgSO 4 • 7 H20 1.17, NaHCO 8 14.9, dex- 
trose 5.5, CaNoe EDTA 0.026, CaC12 1.6) for -20 hour 
storate. Preliminary experiments showed that this 
storage period did not significantly alter responses in 
arteries from either SHRSP or WKY rats. Fatty and 
connective tissue was removed from the thoracic aorta 
and carotid arteries, and the vessels were cut into 
helical strips (2 mm x 15 mm for aorta; 0.7 m m ×  10 
mm for carotid arteries). The endothelium was re- 
moved by gentle rubbing of the intima with a cotton 
swab. Functional removal of the endothelium was con- 
firmed by lack of relaxation to acetylcholine after a 
phenylephrine-induced contraction. Vascular strips 
were mounted on stainless steel tissue hangers and 
suspended in a muscle bath containing PSS main- 
tained at 37°C and aerated with 95% 02 and 5% COs. 
Strips were allowed to equilibrate for 90 minutes with 
a passive force of 1.5 and 0.6 g for aorta and carotid 
arteries, respectively. Drugs were added directly to 
the bath and isometric contractile force was measured 
using Grass FT.03 force transducers and was re- 
corded on a Grass polygraph. Between responses, ag- 
onists were rinsed from the tissue bath and strips 
were allowed to recover to baseline values. Contrac- 
tile responses to angiotensin II were measured in 
thoracic aorta. Cumulative concentration-response 
curves to phenylephrine were generated using carotid 
arteries. 
Plasma renin activity assays were conducted on 
blood samples taken from anesthetized rats according 
to the method described by Sessler et al. [11]. Ali- 
quots of incubation media, plasma, homogenates, and 
gel elutions were combined with substrate prepared 
from 40 hour nephrectomized rats. After incubation, 
the angiotensin I generated was measured using a ra- 
dioimmunoassay kit (New England Nuclear, Boston, 
MA). 
Drugs 
Angiotensin II, hydralazine hydrochloride, and hydro- 
chlorothiazide were purchased from Sigma Chemical 
(St. Louis, MO). Phenylephrine hydrochloride was ob- 
tained from the University of Michigan Hospital Phar- 
macy (Ann Arbor, MI), and Ramipril was the gener- 
ous gift of the Upjohn Co. (Kalamazoo, MI). 
Laboratory chow containing 0.0025% ramipril by 
weight was prepared for this study by Purina Mills 
(Richmond, IN). Hydralazine and hydrochlorothiazide 
were prepared in tap water. All other drugs were 
prepared and diluted in deionized water. Other chemi- 
cals used in this study were of reagent grade. 
Statistical analysis 
Data are expressed as mean _+ standard error of the 
mean (SEM). Unpaired Student's t tests were used to 
determine statistical significance between SHRSP 
and WKY rats and within groups. A p value <0.05 
was considered significant. The Bonferroni correction 
was applied to adjust for multiple comparisons. EC10 
values were determined following graphical represen- 
tation of normalized concentration-response curves. 
Blood pressure correlation with vascular responses 
were calculated using linear regression analysis. 
R e s u l t s  
Rats were treated with hydral/HCTZ or ramipril 
from 6 to 10 weeks of age, and blood pressures and 
weights were measured until 17 weeks of age. Control 
rats received no treatment. Figure 1 illustrates the 
effect of the antihypertensive treatments on the time 
course of systolic blood pressure and weight develop- 
ment in genetically normotensive and hypertensive 
rats. As seen in Figure 1, both antihypertensive regi- 
mens were effective in lowering systolic blood pres- 
sure in both WKY (panel A) and SHRSP (panel B) 
during the treatment period. After cessation of the 
treatments, systolic blood pressures of the WKY rats 
gradually approached control levels. At 16.5 weeks of 
age there was no statistical difference in systolic blood 
pressure among WKY rat groups. SHRSP animals 
treated with hydral/HCTZ showed an increase in sys- 
tolic blood pressure after cessation of the treatment; 
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Fig. 1. Antihypertensive regime effects on blood pressure and body weight. A: Line graph showing indirect systolic blood pressure 
of W K Y  rats 4.5-16.5 weeks of age receiving no treatment (n = 7), hydralazine/HCTZ treatment (n = 6), or ramipril  treatment 
(n = 8). B: Line graph showing indirect systolic blood pressure of SHRSP rats 4.5-16.5 weeks of age receiving no treatment (n = 
8), hydralazine/I-ICTZ treatment (n = 5), or ramipril treatment (n = 8). C: Line graph showing body weight of  W K Y  rats 
4.5-16.5 weeks of age receiving no treatment (n = 7), hydralazine/HCTZ treatment (n = 6), or ramipril  treatment (n = 8). D: 
Line graph showing body weight of SI-IRSP rats 4.5-16.5 weeks of  age receiving no treatment (n = 8), hydralazine/HCTZ treat- 
ment (n = 5), or ramipril treatment (n = 8). Al l  data are reported as means +_ S E M  values. Data points at age 15.5 weeks were 
excluded due to technical reasons. *p < .01 compared to untreated group by t test in week 16.5 of blood pressures and at all data 
points in body weight measurements. 
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at 14.5 weeks of age there was no significant differ- 
ence between the hydral/HCTZ-treated SHRSP and 
the untreated SHRSP, while at 16.5 weeks of age 
there was a significant difference (198 _+ 6 vs. 217 - 
3 mmHg), though not to the magnitude of the rami- 
pril-treated SHRSP. Ramipril-treated SHRSP did not 
show as great a rise in blood pressure, and systolic 
blood pressure remained significantly lower than un- 
treated levels at 16.5 weeks of age (168 _ 2 vs. 217 
-+ 3 mmHg). The systolic blood pressures of the rami- 
pril-treated SHRSP, however, were still significantly 
higher than those in WKY (131 _-_ 4 mmHg). The time 
course for weight gain showed no statistical differ- 
ences among treatments in SHRSP or WKY, although 
there was a trend towards higher body weights in 
WKY animals that received hydral/HCTZ versus con- 
trol WKY animals and lower body weights in ramipril- 
treated WKY animals versus untreated controls. 
Figure 2 illustrates the time course of force devel- 
opment in aortic strips exposed to 0.1 ~M AII. Fol- 
lowing addition of AII to the muscle bath, aortic re- 
sponses were characterized by a sharp, rapid "phasic" 
response that was particularly pronounced in SHRSP. 
Following this phasic response there was a more grad- 
ual contractile response and maintenance of tone. The 
maximal force development or peak response was 
measured as the greatest trension observed during 
this tonic phase. Marked oscillatory contractile activ- 
ity was occasionally observed in SHRSP but never in 
WKY rats. Because of the low frequency of this event, 
however, it was not possible to determine whether 
either antihypertensive treatment affected this phe- 
nomenon. A single, maximal concentration of AII was 
utilized because of the tachyphylactic properties of 
AII on contractile responsiveness in rat arteries. 
Peak responses to AII were not significantly differ- 
ent among any of the groups except untreated WKY 
(untreated WKY, 224 _ 38 mg; hydral/HCTZ-treated 
WKY, 320 - 55 rag; ramipril-treated WKY, 401 - 
36 mg; untreated SHRSP, 352 _ 33 mg; hydral/ 
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Fig. 2. Representative tracing of force development in re- 
sponse to angiotensin H (0.1 tiM) in thoracic aorta from 
WKY (top) and SHRSP (bottom) rats. Responses were charac- 















Fig. 3. Profile of contractile responses to 0.1 ttM angiotensin 
H. Phasic response to angiotensin H in WKY and SHRSP 
control and treated rats. Values are expressed as percent of 
peak response to angiotensin H. All data are expressed as 
means +_ SEM values, n values: WKY untreated (7), WKY 
hydralazine/HCTZ (6), WKY ramipril (8), SHRSP untreated 
(8), SHRSP hydralazine/HCTZ (5), SHRSP ramipril (8). *p 
< .05 compared with untreated WKY by Student's test. 
HCTZ-treated SHRSP, 354 _ 70 mg; ramipril- 
treated SHRSP, 388 +_ 51 mg). 
Figure 3 illustrates phasic contractile respon- 
siveness to 0.1 ~M AII in aortic segments from all 
WKY and SHRSP groups. Contractile responsiveness 
to angiotensin II was characterized because of its rela- 
tionship to the experimental intervention (ACE inhib- 
itor). According to the hypothesis that inhibition of 
angiotensin II generation during development would 
have long-term effects, it would logically follow that 
some alteration in responsiveness to AII in adulthood 
may occur. The phasic component of contraction in 
vascular smooth muscle corresponds to calcium re- 
lease from intracellular stores. It has previously been 
observed that this phasic response in response to cer- 
tain agonists is greater in arteries from SHRSP than 
in arteries from WKY rats [12]. Phasic responses elic- 
ited by AII were easily characterized in aortae from 
the treated and untreated SHRSP and WKY rats be- 
cause of the distinct separation between the phasic 
and tonic portions of contraction (Figure 3). This dif- 
ference in phasic contractile responsiveness was stud- 
ied with the hypothesis that ACE inhibition during 
development would reverse this increase in phasic 
contractile responsiveness to AII in aortae from 
SHRSP. 
In all groups, aorta from SHRSP animals showed 
significantly greater levels of phasic contractile re- 
sponse to AII than WKY animals. Antihypertensive 
treatment had no significant effect on phasic contrac- 
tile responses in the WKY or SHRSP groups. Both 
treatments tended to cause a decrease in phasic re- 
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sponse from untreated levels in SHRSP, but this de- 
crease was not statistically significant. However, this 
may be due to insufficient statistical power rather 
than a lack of physiological difference. Plasma renin 
activity was not significantly different among animal 
groups (untreated WKY, 23.9 -+ 2.5 ng/ml/hr; hydral/ 
HCTZ-treated WKY, 28.0 -+ 4.6 ng/ml/hr; rami- 
pril-treated WKY, 27.8 -+ 3.1 ng/ml/hr; un- 
treated SHRSP, 26.0 _+ 1.8 ng/ml/hr; hydral/HCTZ- 
treated SHRSP, 30.7 _+ 0.8 ng/ml/hr; rami- 
pill-treated SHRSP, 23.1 + 2.7 ng/ml/hr). 
As stated earlier, the only significant difference 
when comparing the peak responses to AII among the 
animal groups is found in the untreated WKY group. 
It is interesting to note, however, that when the pha- 
sic response to AII is normalized to the respective 
peak responses, the difference between the treated 
and untreated WKY groups is not present. Further, 
the alteration in phasic response in the SHRSP groups 
is only apparent when the values are normalized to 
peak response values. We therefore interpret the 
variation in peak response in the untreated WKY ani- 
mal to be representative of a variation in cross- 
sectional area or other similar factor that, when inter- 
preted in isolation, is not significant, but rather 
functions as a normalization standard for other values 
so that "real" differences may be observed. 
The enhanced contractile responsiveness in hyper- 
tension also involves an adrenergic component. Re- 
sponsiveness to the adrenergic agonist, phenyleph- 
fine, was taken as a reflection of this adrenergic 
component of hypertension. Figure 4 illustrates the 
concentration-response curves to phenylephrine in ca- 
rotid arteries from treated and untreated SHRSP and 
WKY rats. Panel A shows the cumulative concentra- 
tion response curve to PE in carotid arteries from 
WKY groups. Treatment during development did not 
significantly alter sensitivity to PE among adult WKY 
rats, though there was a significant difference be- 
tween WKY groups and the untreated SHRSP group 
(on the order of one log unit; indicated by the dotted 
line; replotted data from fight-hand panel). Panel B 
shows the cumulative concentration-response curve to 
PE in carotid arteries from SHRSP groups. Treat- 
ment during development with hydral/HCTZ did not 
significantly affect responsiveness in adult SHRSP. 
Treatment during development with ramipril, how- 
ever, significantly shifted the concentration-response 
curve to the right in the adult SHRSP, yielding a 
curve that was characteristic of the responses from 
WKY groups. Threshold values to PE were taken as 
a measure of altered vascular responsiveness. In this 
case, the threshold value was defined as the concen- 
tration of PE that produced 10% of the maximal re- 
sponse to PE (EC10). Figure 5 shows the threshold 
(EC10) for PE-induced contractions in the carotid ar- 
tery from all animal groups. Carotid arteries from 
SHRSP showed a greater sensitivity to PE (lower 
EC10) than carotid arteries from WKY rats. Treat- 
ment with hydral/HCTZ did not significantly alter 
sensitivity to PE in carotid arteries from either strain. 
Threshold values to PE in carotid arteries from rami- 
pril-treated rats, however, were significantly higher 
than values from untreated SHRSP but were not sig- 
nificantly different from WKY levels. Thus, treatment 
with ramipril prevented the development of increased 
sensitivity to PE in SHRSP. 
Figure 6 examines the relationship between termi- 
nal blood pressure and vascular reactivity. •Weighted 
linear regression analysis using all animal groups was 
used to calculate correlations between blood pressure 
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Fig. 4. Concentration-response curve to phenylephrine in carotid arteries from W K Y  and SHRSP control and treated rats. Cumu- 
lative concentrations of phenylephrine were introduced into the bath. Five-minute intervals were maintained between doses, n val- 
ues: W K Y  control (7), W K Y  hydralazine/HCTZ (6), W K Y  ramipril (8), SHRSP control (8), SHRSP hydralazine/HCTZ (5), 
SHRSP ramipril (8). *p < .05 by Student's t test. 
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Fig. 5. EClo threshold values of phenylephrine-induced contraction in carotid arteries from SHRSP and WKY rats. Average con- 
centration of PE that elicits a contractile response equal to 10% of maximal contraction. ECIo values were determined following 
graphical representation of normalized concentration-response curves. Data are expressed as means +_ SEM values, n values: 
WKY control (7), WKY hydralazine/HCTZ (6), WKY ramipril (8), SHRSP control (8), SHRSP hydralazine/HCTZ (5), SHRSP 
ramipril (8). Multiple t tests with Bonferonni correction were used to determine statistical significance. *p < .01 when compared 
with the untreated WKY group, tp < .01 when compared with the untreated SHRSP group. 
tionship between contractile responsiveness to 0.1 ~M 
AII in thoracic aorta and systolic blood pressure. 
Analysis revealed that the ramipril-treated SHRSP 
point did not significantly influence the slope of the 
correlation line. Figure 6B illustrates the relationship 
between threshold values to PE in carotid arteries 
and systolic blood pressure. Weighted linear regres- 
sion revealed that the ramipril-treated SHRSP point 
significantly influenced the slope of the correlation 
line; this point does not belong on the correlation line. 
D i s c u s s i o n  
The present study confirms previous work demon- 
strating that treatment with an ACE inhibitor early 
in the development of the genetically hypertensive an- 
imal prevents the full expression of hypertension in 
adulthood [6-10]. Changes in systolic blood pressure 
and vascular responsiveness were observed 7 weeks 
after cessation of the ACE inhibitor treatment. Con- 
tractile responsiveness to AII, shown to be altered in 
the hypertensive animal, was not significantly af- 
fected by treatment with ramipril but was correlated 
with terminal systolic blood pressure. Therefore, con- 
tractile responsiveness to AII does not appear to be 
associated with an AII-mediated genetic program in 
SHRSP and may be secondary to changes in blood 
pressure. In contrast, sensitivity to PE in the rami- 
pril-treated SHRSP was not significantly different 
from WKY, and this change in sensitivity did not cor- 
relate with blood pressure. These results support a 
role for an AII-sensitive mechanism that may affect 
the development of genetic hypertension. 
In terms of blood pressure development, it was 
clear that both ramipril and hydral/HCTZ were effec- 
tive in reducing systolic blood pressure in both the 
WKY and SHRSP during the treatment period. After 
cessation of the treatment, however, the blood pres- 
sures of both treated WKY groups approached those 
of the untreated WKY, and at 17 weeks of age there 
was no significant difference among the WKY ani- 
mals. Thus, antihypertensive treatment during the 
putative "critical period" in the normotensive animal 
does not seem to interfere with normal blood pressure 
development. After cessation of treatment in the 
SHRSP groups, the blood pressures of the hydral/ 
HCTZ-treated animals approached untreated SHRSP 
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Fig. 6. Correlation between vascular responsiveness and average terminal blood pressure from treated and untreated WKY and 
SHRSP. A plots the correlation between contractile responsiveness to 0.1 t~I Angiotensin H (AII) in thoracic aorta and terminal 
systolic blood pressure• A linear regression was performed using all groups, and it was determined that a positive correlation ex- 
ists between blood pressure and contractile responsiveness to 0.1 ~ AII. None of the groups lie significantly off the linear regres- 
sion. B plots the correlation between ECIo threshold values to phenylephrine in carotid arteries and average terminal blood pres- 
sure. A linear regression was performed using all points, and it was determined that a positive correlation exists between blood 
pressure and vascular responsiveness to phenylephrine. Only ramipril-treated SHRSP lie significantly off the linear regression. 
All data are expressed as means +_ SEM values, n values: WKY untreated (7), WKY hydralazine/HCTZ (6), WKY ramipril (8), 
SHRSP untreated (8), SHRSP hydralazine/HCTZ (5), SHRSP ramipril (8). 
blood pressure levels though at 17 weeks of age, and 
there was still a significant difference. In contrast, 
the blood pressures of the ramipril-treated SHRSP 
animals plateaued significantly earlier and remained 
approximately 50 mmHg lower then the untreated 
SHRSP at 17 weeks of age. Clearly, simple reduction 
of blood pressure through the use of hydral/HCTZ 
during development did not account for the disparity 
between the untreated and rampril-treated SHRSP. 
Further, changes in body weight cannot account for 
this effect, as there were no significant differences in 
body weight among WKY and SHRSP. Rather, the 
chronic blood pressure-lowering effect of ramipril ap- 
peared to be the result of alterations in an AII- 
sensitive mechanism during a critical period of devel- 
opment. This conclusion is supported by the 
observation of Harrap et al. [6] that administration of 
AII along with ACE inhibitors resulted in the full 
expression of genetic hypertension. The question re- 
mains, however, as to what changes AII is effecting 
in the cardiovascular system in order to produce this 
antihypertensive effect. 
One possible mechanism is alterations of the angio- 
tensin-renin system. Intuitively, it might be expected 
that long-term changes associated with early ACE in- 
hibition would affect responsiveness to AII in vascular 
smooth muscle or alter circulating AII levels. Previ- 
ous studies have demonstrated an increased contrac- 
tile responsiveness to AII in SHR through greater 
postsynaptic effects of the peptide [13], greater pres- 
sor [14] and slow-pressor [15] response to AII in SHR, 
and greater AII-stimulated increases in intracellular 
calcium [16]. Further, long-term treatment with ACE 
inhibitors has been shown to cause alterations in the 
renin-angiotensin system both centrally and peripher- 
ally that were manifested by changes in receptor bind- 
ing and responsiveness to AII [17]. In this study we 
observed an increased contractile responsiveness in 
SHRSP to AII; however, these results were not sig- 
nificantly affected by ACE inhibitor treatment. 
Blocking AII generation during development does not 
appear to have any long-term effect on contractile re- 
sponsiveness to AII. Further, plasma renin activity 
was not significantly different among the study 
groups. Hence, the target molecule for the long-term 
effects of ACE inhibition is unlikely to be AII. The 
increased responsiveness to AII in SHRSP, there- 
fore, may be mediated by another genetic program 
that is regulated by some factor other than AII. An- 
other possibility is that the increased responsiveness 
is secondary to the elevated blood pressure in SHRSP 
versus WKY. A second possible mechanism through 
which AII may modulate blood pressure is increased 
vascular smooth muscle growth. Investigators report 
that AII may mediate smooth muscle cell hypertrophy 
through changes in cytoskeletal [18,19] and growth 
factors [20]. While structural alterations in vascular 
smooth muscle were not examined in the present 
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study, recent reports suggest that vascular structure 
is a poor predictor of long-term hypertensive levels in 
SHR [9]. 
A third possibility is that reduced bradykinin deg- 
radation, which also occurs with administration of 
ACE inhibitors, may be partially responsible for the 
long-term effects of ACE inhibitors on blood pressure 
and vascular reactivity. Studies performed by Harrap 
et al. [6], however, show that long-term effects of an- 
tihypertensive treatment were not present when AII 
was coadministered with the ACE inhibitor. Further, 
persistent effects were also observed when the AII 
antagonist, losartan, was administered to hyperten- 
sive rats [9]. Therefore, it seems unlikely that brady- 
kinin plays a major role in this phenomenon. 
A fourth possible target for AII is the adrenergic 
response of vascular smooth muscle in hypertension. 
Studies have shown that AII can augment both the 
presynaptic and postsynaptic response to norepineph- 
rine [13,21]. Draper et al. [22] report that AII en- 
hanced the responses to peripheral nerve stimulation 
in preparations from normotensive and hypertensive 
animals, and that the enhancement was significantly 
greater in preparations from hypertensive animals. 
The present study characterized differences in sensi- 
tivities to phenylephrine in WKY and SHRSP. Treat- 
ment of SHRSP with ramipril prevented the develop- 
ment of increased sensitivity to phenylephrine that is 
characteristic of genetic hypertension. Moreover, the 
sensitivity to PE of the ramipril-treated SHRSP was 
not significantly different from those of the WKY 
groups. The sensitivity to PE does not appear to be 
a secondary effect of the reduced blood pressure in 
the ramipril-treated rat because hydral/HCTZ does 
not alter sensitivity to PE despite lowering blood 
pressure. Because the blood pressure of the ramipril- 
treated SHRSP is intermediate between the pres- 
sures of the untreated-SHRSP and the WKY groups, 
an association with blood pressure would dictate that 
the sensitivity to PE of the ramipril-treated animal 
would lie intermediate between the two groups. How- 
ever, as shown in Figure 6, the EC10 for the ramipril- 
treated SHRSP is neither intermediate between the 
two groups nor correlated with blood pressure. This 
is further supported by the observation that ramipril- 
treated SHRSP show intermediate contractile re- 
sponses to AII that both correlate with terminal blood 
pressure. Based on these data, we conclude that sensi- 
tivity to PE is determined by a genetic program that 
is influenced by AII. Thus, altered sensitivity to PE 
through the prevention of the enhancement of periph- 
eral nerve stimulation by AII reported by Draper may 
be partially responsible for the attenuation of blood 
pressure observed in the ACE inhibitor-treated 
SHRSP. 
It has been suggested that changes in vascular re- 
sponsiveness in those subjects undergoing antihyper- 
tensive treatment may simply be the result of lower 
blood pressure. A recent study by Harrap et al. [23] 
attempts to address this issue by coadministering al- 
dosterone with the ACE inhibitor treatment in order 
to sustain high blood pressure during the critical pe- 
riod. The blood pressure-lowering effect is not seen 
in these animals, and Harrap interprets this as mean- 
ing the effects of Ang II are most likely dependent on 
its blood pressure-lowering ability. The results of our 
study directly refute this interpretation by illustrat- 
ing that decreased blood pressure alone during the 
critical period is not sufficient to produce the long- 
term effect. However, as Harrap also suggests, it is 
possible that AII does not exert its effects through 
either direct trophic or blood pressure-lowering abil- 
ity but rather may be due to its effects on electrolyte 
balance through mediators such as aldosterone. 
Further, experimental observations from other 
laboratories indicate that ACE inhibitors have effects 
on vascular responsiveness to agonists that are inde- 
pendent of its blood pressure-lowering effect. In a 
study by Sada et al. [24], SHR treated with hydral- 
azine did not show changes in vascular responsiveness 
that were seen in SHR treated with ACE inhibitors, 
despite both sets of rats having blood pressures that 
were comparable (-130 mmHg). Therefore, it ap- 
pears that ramipril is exerting its effects on the vascu- 
lature by some other means than solely lowering blood 
pressure. 
In a study by Harrap et al. [6], sensitivity of the 
mesenteric artery from ACE inhibitor-treated SHR 
to norepinephrine was not significantly different from 
untreated SHR levels. Based upon this observation, 
they concluded that differences in contractile respon- 
siveness were the result of structural changes rather 
than changes in the sensitivities of smooth muscle 
cells to norepinephrine. The present study shows that 
there was an altered sensitivity to phenylephrine in 
the carotid arteries from SHRSP and WKY rats. 
Moreover, ACE inhibition during development of the 
SHRSP does indeed alter sensitivity to phenylephrine 
in carotid arteries to levels observed in the WKY ca- 
rotid artery. These separate observations concerning 
sensitivity to catecholamines may be due to different 
properties of the respective blood vessles. Indeed, it 
has been shown that different vascular beds possess 
different structural and functional characteristics. 
It is interesting to note that treatment with either 
hydralazine [25] or hydrochlorothiazide [26] have been 
shown to result in slightly higher plasma renin activ- 
ity levels. Unfortunately, since plasma renin activity 
levels were not measured during the experimental 
preparation of the animals, any comment on whether 
the AII levels are actually elevated or unchanged are 
purely speculative. However, it is clear that the "all 
or none" effect on development of blood pressure, as  it 
appears in the literature, is not present in the animals 
treated with HCTZ/hydralazine. This supports the 
hypothesis that some genetic element is called into 
play during the development of the hypertensive ani- 
mal that appears to require AII in order to be active. 
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It follows that a slight elevation of AII levels should 
not affect this genetic program. 
In summary, this study demonstrates that (a) a 
portion of blood pressure in the adult SHRSP is under 
the control of an AII-mediated genetic program that is 
activated early in development; (b) phasic contractile 
responsiveness to AII is augmented in SHRSP and 
this vascular trait is not under the control of an AII- 
mediated genetic program; and (c) sensitivity to phen- 
ylephrine is increased in the adult SHRSP and this 
vascular trait is under the control of an AII-mediated 
genetic program. These data support the hypothesis 
that vascular abnormalities in SHRSP arise from a 
particular genetic program that is initiated early in 
development and contributes to the full expression of 
hypertension in the adult animal. 
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